KIORA PHARMACEUTICALS INC

KPRXNASDAQ

🏆 #4946 by market capEarnings Nov 5US Equity

$2.72▲ $0.06 (+2.26%)

After hours · at close

🔔

Track KPRX

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 2.3%

7d▲ 0.0%

14d▲ 4.8%

30d▲ 0.0%

ytd▲ 39.5%

1y▲ 4.2%

🏦Market Cap

$12M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

0.7x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $2.68 – $2.75
52-Week Range: $1.76 – $2.95
Volume: $6.51B
Avg Volume: $8.07B
Shares Outstanding: 4.4M
Next Earnings: Dec 5, 2026

Fundamentals Snapshot

Annual Revenue: $16M
Last Q Revenue: $4M
P/E Ratio: —
P/S Ratio: 0.7x
EPS (TTM): $-2.47
Dividend Yield: —
Dilution (1yr): +36.8%

Why Investors Own KPRX

✓High-growth profile — revenue up +46.3% YoY with expanding US Equity exposure.
✓Healthy economics — 53% gross margin and 27% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

KIORA PHARMACEUTICALS INC

KPRX

Financial Trends

Revenue

$0▼ −100.0% YoY

Operating Income

−$9M▼ −309.7% YoY

Free Cash Flow

−$10M▼ −217.8% YoY

Shares Outstanding

4.1M▲ +36.8% YoY

Net Cash

$8M▲ +$5M YoY

StockOtter · stockotter.space

About KIORA PHARMACEUTICALS INC

Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.

🦦